Evaluation of the criteria for renewal of LHRH agonists in patients with prostate cancer: results of the ANAREN Study

Jesús Calleja-Escudero, Víctor Barrondo, Andrés Rodriguez-Alonso, Francisco Gómez-Veiga, Joan Bestard, Antonio Gómez-Caamaño, Anne-Sophie Grandoulier, Maria Pérez-Sampietro, Venancio Chantada-Abal, Raúl Poza de Celis, on behalf of ANAREN Study Group


Introduction: Injectable extended-release formulations of luteinizing hormone-releasing hormone agonists (LHRHa) have simplified the treatment of prostate cancer with a satisfactory level of androgen castration. This study aims to determine the percentage of patients whose initial LHRHa prescription was renewed during follow-up, how many changed formulation and how their quality of life evolved.

Methods: This is an observational, prospective, multicentre study of men with prostate cancer who were to receive treatment with LHRHa (triptorelin every 3 or 6 months, leuprorelin every 3 or 6 months, or goserelin every 3 months) for 24 months. The treatment used was recorded and quality of life was assessed (QLQ-PR25 questionnaire) at four follow-up visits.

Results: A total of 497 men (median age 75 years) were evaluated. The median exposure to LHRHa was 24 months. The initial prescription was renewed in 95.7% at follow-up 1 and 75% at follow-up 4. The main reason for changing from a 6-month to a 3-month formulation was a preference for sequential treatment (according to the investigator) and to see the physician more frequently (according to the patient). The main reason for switching from the 3-month to 6-month formulation was simplification of treatment (according to the investigator) and for convenience (according to the patient). Findings in the QLQ-PR25 questionnaire revealed no changes in urinary or bowel symptoms, though an improvement in sexual activity was reported. Practically all investigators and patients were satisfied/very satisfied with the treatment.

Conclusion: Changes in formulation were scarce and generally justified by convenience factors or personal preferences. Patients maintained a good health status, with a high rate of retention of LHRHa treatment.

Clinical Trial Registration: Study number: A-ES-52014-224.

A plain language summary is provided as supplementary material (available at: https://www.drugsincontext.com/wp-content/uploads/2024/05/dic.2024-2-2-Suppl.pdf).

Article Details

Article Type

Original Research



Publication Dates

Accepted: ; Published: .


Calleja-Escudero J, Barrondo V, Rodriguez-Alonso A, Gómez-Veiga F, Bestard J, Gómez-Caamaño A, Grandoulier AS, Pérez-Sampietro M, Chantada-Abal V, Poza de Celis R, on behalf of ANAREN Study Group. Evaluation of the criteria for renewal of LHRH agonists in patients with prostate cancer: results of the ANAREN Study. Drugs Context. 2024;13:2024-2-2. https://doi.org/10.7573/dic.2024-2-2

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.